Xin Du

Some founders start with a market. Xin Du started with a smell.

In 2020, working in a laboratory, Du caught the pure aroma released by cured tobacco for the first time. By his own account it was a small, almost incidental moment. But it lodged. Out of it came a question that would reorganize his career: could there be a genuinely different option for the roughly 1.5 billion people around the world who smoke? That question became WONZ Technology, the medical-device and digital-health company he founded the same year and still leads as CEO.

To understand why a single lab moment could turn into a company, it helps to know what Du had already done by then. He is a trained scientist, with postdoctoral research experience tied to the Dana-Farber Cancer Institute and Harvard Medical School. He had also spent time on the other side of the table, in venture capital, as a founding partner at Niniu Capital and the founder of Neeo Fund. As an investor he backed startups including the social app Soul. He knew, in other words, both how the science worked and how companies got funded. WONZ is what happened when he decided to stop choosing between the two.

The investor who wanted to build

There is a well-worn path in technology from operator to investor. Founders sell a company, join a fund, and spend the rest of their careers advising the next generation. Du ran that path in reverse. He had the venture partnership, the portfolio, the seat that most builders spend a decade trying to earn. And he walked away from the comfort of it to start something with his own name on the risk.

That choice tells you something about how he thinks. An investor's job is to spot the person who will build the thing. At some point Du seems to have decided he would rather be that person than keep betting on them. His LinkedIn headline reads, plainly, "bioelectronics venture builder." Not investor. Not scientist. Builder.

The dopamine reward mechanism is closely related to commercial prosperity, but we hope to reverse this mechanism to solve health problems and prevent disease. Xin Du, on WONZ's core idea

That line is the intellectual center of the company. A great deal of modern technology is engineered to capture attention by triggering the brain's reward loop - the same loop that underlies most consumer habits. Du's thesis is contrarian: take that mechanism, understood well enough, and point it in a constructive direction rather than an extractive one. It is a scientist's framing of a consumer problem, and it is the sort of idea that only makes sense coming from someone who has stood in all three rooms - the lab, the fund, and the factory.

Building quietly, and fast

WONZ is not a headcount story. It runs lean, the kind of team you could fit around one table. What it has instead is engineering density. By 2023, three years in, the company had filed more than 111 patent applications - an unusual pace for a startup of its size. That same year it landed on the POC50 list of the top 50 startup companies, an early signal that people outside the company were paying attention.

The money followed the work. Early rounds brought in over 100 million yuan from investors including Niniu Capital and XVC. Later financing, at the Series A stage, added state-linked backing from Zhejiang Yuhuan State Investment, tied to plans for an automated production base. For a hardware company, that mix matters: patents prove the science, but factories prove you can ship it. Du has been assembling both at once.

A company with two addresses

Du's working life is split across geographies in a way that is increasingly common for hardware founders but still logistically demanding. He is based in San Francisco. WONZ is registered in Hong Kong. Production runs through mainland China, with bases developed in Yuhuan and Hainan, the latter chosen to take advantage of free-trade-port policy. This is not glamour travel; it is the practical reality of building physical products, where the science, the money, and the manufacturing rarely sit in the same time zone.

The payoff of that sprawl showed up in 2024, when WONZ moved beyond its home market and secured the platform rights to begin selling into Australia, Germany, and Japan. Three continents, four years after a moment in a lab. For a company that started with a mission almost comically large - a better option for well over a billion people - the early international footprint is a sign that the ambition was not only rhetorical.

An alternative health solution for the 1.5 billion smokers around the world. The founding idea behind WONZ Technology

The scientist's playbook

It is tempting to read Du's story as three separate careers - researcher, investor, founder - stacked on top of each other. It is more accurate to see them as one continuous apprenticeship. The lab taught him how to interrogate a claim until it either held up or fell apart. Venture capital taught him what separates a business from a science project: distribution, timing, the willingness of a customer to actually pay. WONZ is where those two educations meet.

You can see the researcher in how the company is built. It leads with patents rather than press. It frames its product thesis in terms of mechanism rather than marketing. And it treats a large, hard problem as something to be worked, patiently, over years - the way you would work a research question, not a growth curve. Whether that patience pays off at global scale is still an open question. But the approach is unmistakably his.

For now, Xin Du remains in the middle of the build. The team is still small. The patents keep accumulating. The markets keep opening, one country at a time. And the whole enterprise still traces back to a moment most people would have walked right past - the kind of moment that only becomes a company when the person noticing it happens to have spent years learning exactly what to do next.